|
5217
|
Basal cell carcinoma
|
12
|
5.79E−07
|
BMP2,FZD1,GLI3,TCF7,TCF7L1,WNT1,WNT16,WNT2,WNT3A,WNT5A,WNT6,WNT7B
|
|
4340
|
Hedgehog signaling
|
11
|
1.25E−06
|
BMP2,GAS1,GLI3,IHH,WNT1,WNT16,WNT2,WNT3A,WNT5A,WNT6,WNT7B
|
|
4340
|
Hedgehog signaling
|
11
|
1.25E−06
|
CTBP2,DKK1,FZD1,NFATC1,SFRP2,SFRP5,TCF7,TCF7L1,WNT1,WNT16,WNT2,WNT3A,WNT5A,WNT6,WNT7B
|
|
4310
|
Wnt signaling
|
15
|
2.78E−05
|
CREB3L1,FZD1,GNAS,TCF7,TCF7L1,WNT1,WNT16,WNT2,WNT3A,WNT5A,WNT6,WNT7B
|
|
4916
|
Melanogenesis
|
12
|
9.14E−05
|
BCL2,BMP2,COL4A2,CTBP2,FGF12,FGF3,FGFR1,FZD1,GLI3,IGF1R,JUP,PDGFRA,TCF7,TCF7L1,TGFB1,WNT1,WNT16,WNT2,WNT3A,WNT5A,WNT6,WNT7B
|
|
5200
|
Pathways in cancer
|
22
|
0.00015
|
BMP2,FZD1,PPP2R2A,STK3,TCF7,TCF7L1,TGFB1,WNT1,WNT16,WNT2,WNT3A,WNT5A,WNT6,WNT7B
|
|
4390
|
Hippo signaling
|
14
|
0.000203
|
CAV1,FGF12,FGF3,FGFR1,FZD1,IGF1R,IGF2,SDC2,TGFB1,TWIST2,WNT1,WNT16,WNT2,WNT3A,WNT5A,WNT6,WNT7B
|
|
5205
|
Proteoglycans in cancer
|
17
|
0.000286
|
CDK14,IGF1R,IGFBP3,JUP,MEIS1,NGFR,NR4A3,PAX7,SIX1,TLX3,WNT16,WT1
|
|
5202
|
Transcriptional misregulation in cancer
|
12
|
0.01
|
BCL2,CREB3L1,CREB5,FGFR1,IGF1R,PDGFRA,TCF7,TCF7L1
|
|
5215
|
Prostate cancer
|
8
|
0.0177
|
AVPR1A,CACNA1I,CD38,GNAS,GRIN2A,GRIN2C,ITPKB,NOS1,PDE1B,PDGFRA,TACR1
|
|
4020
|
Calcium signaling
|
11
|
0.0474
|
CTBP2,DKK1,FZD1,NFATC1,SFRP2,SFRP5,TCF7,TCF7L1,WNT1,WNT16,WNT2,WNT3A,WNT5A,WNT6,WNT7B
|
|
4340
|
Hedgehog signaling
|
11
|
1.25E−06
|
CREB3L1,FZD1,GNAS,TCF7,TCF7L1,WNT1,WNT16,WNT2,WNT3A,WNT5A,WNT6,WNT7B
|
